US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Share price’s recent ride doesn’t track with analysts’ regard for C&D’s results and outlook.

Health, personal and household care product marketer says raising its annual guidance model from 3% organic growth to 4% driven by expectations for international sales growth, a return to volume-driven sales growth and outlook for Hero and TheraBreath brands.

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.